Recovery of the ability to induce immune resistance against L1210 lymphatic leukemia in semisyngeneic CD2F1 mice after lethal irradiation and reconstitution with bone marrow purged of leukemia with mafosfamide (ASTA Z 7654).
Balb/c x DBA/2 F1 (CD2F1) mice were lethally irradiated (TBI) and reconstituted with syngeneic bone marrow cells (SBMT) untreated or treated with mafosfamide (ASTA Z 7654) for ex vivo purging of semisyngeneic L1210 leukemia (TBI + SBMT or TBI + SBMT-Maf mice, respectively). At various times after irradiation and reconstitution mice were injected intraperitoneally four times at weekly intervals with 10(6) immunogenic L1210-Maf cells (L1210 cells treated in vitro with mafosfamide for inhibition of their growth in vivo). As positive controls we immunized normal (non-irradiated) CD2F1 mice. Full resistance against L1210 leukemia (as compared to normal immunized mice) could be obtained in TBI + SBMT and TBI + SBMT-Maf mice when the immunization procedure was started from day +28 or day +56 after transplantation, respectively. Earlier immunization of TBI + SBMT mice (from day +14) or TBI + SBMT-Maf mice (from day +14 or +28) caused only partial resistance against the leukemia.
Skórski
T
T
Department of Cytophysiology, Medical Center of Postgraduate Education, Warsaw, Poland.
Kawalec
M
M
D000818:Animals; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007114:Immunization; D007939:Leukemia L1210 / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D051379:Mice; D014916:Whole-Body Irradiation
C048341:mafosfamide; D003520:Cyclophosphamide